Your browser is no longer supported. Please, upgrade your browser.
Settings
GEMP Gemphire Therapeutics Inc. daily Stock Chart
GEMP [NASD]
Gemphire Therapeutics Inc.
Index- P/E- EPS (ttm)-0.97 Insider Own13.60% Shs Outstand16.55M Perf Week-1.08%
Market Cap4.85M Forward P/E- EPS next Y-2.12 Insider Trans0.00% Shs Float6.56M Perf Month-12.17%
Income-13.80M PEG- EPS next Q-0.11 Inst Own18.00% Short Float1.19% Perf Quarter-40.20%
Sales- P/S- EPS this Y47.00% Inst Trans-14.96% Short Ratio0.63 Perf Half Y-69.16%
Book/sh-0.07 P/B- EPS next Y-285.50% ROA-173.10% Target Price2.00 Perf Year-67.44%
Cash/sh0.11 P/C2.55 EPS next 5Y- ROE-419.70% 52W Range0.24 - 1.49 Perf YTD-63.82%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-80.27% Beta2.86
Dividend %- Quick Ratio0.70 Sales past 5Y- Gross Margin- 52W Low23.11% ATR0.04
Employees9 Current Ratio0.70 Sales Q/Q- Oper. Margin- RSI (14)41.41 Volatility15.34% 13.08%
OptionableYes Debt/Eq- EPS Q/Q43.60% Profit Margin- Rel Volume0.45 Prev Close0.32
ShortableYes LT Debt/Eq- EarningsDec 19 AMC Payout- Avg Volume123.99K Price0.29
Recom2.00 SMA20-13.42% SMA50-16.02% SMA200-61.60% Volume55,829 Change-7.66%
Jan-26-18Reiterated H.C. Wainwright Buy $22 → $28
Oct-27-17Resumed Piper Jaffray Overweight $22
Oct-19-17Initiated ROTH Capital Buy
Aug-31-17Initiated H.C. Wainwright Buy $21
Aug-08-17Reiterated Jefferies Buy $32 → $18
Apr-10-17Initiated Piper Jaffray Overweight $30
Dec-06-19 08:43AM  Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals GlobeNewswire -11.00%
Aug-09-19 08:00AM  Gemphire Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-26-19 06:01AM  Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company GlobeNewswire -11.35%
Jul-25-19 10:15AM  Gemphire Flirts With $1 Level As Struggling Biotech Strikes Reverse Merger Deal Benzinga +28.47%
07:21AM  The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug Benzinga
Jul-24-19 04:01PM  Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company GlobeNewswire
Jun-27-19 06:50AM  Gemphire Therapeutics Inc.'s (NASDAQ:GEMP) Path To Profitability Simply Wall St. -15.79%
Jun-26-19 08:00AM  Gemphire Announces Top-Line Data from Familial Partial Lipodystrophy (FPLD) Phase 2a Proof-of-Concept NAFLD/NASH Clinical Trial GlobeNewswire -21.16%
Mar-15-19 08:00AM  Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results GlobeNewswire
Jan-03-19 07:00AM  Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer GlobeNewswire
Dec-25-18 10:10AM  Do Insiders Own Shares In Gemphire Therapeutics Inc. (NASDAQ:GEMP)? Simply Wall St.
Dec-03-18 08:00AM  Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update GlobeNewswire
Nov-19-18 08:40AM  Detailed Research: Economic Perspectives on Cocrystal Pharma, Genius Brands International, Gemphire Therapeutics, Global Water Resources, Infrastructure and Energy Alternatives, and Condor Hospitality Trust What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-08-18 04:01PM  Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Sep-25-18 08:30AM  The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering Benzinga
Sep-24-18 05:06PM  Gemphire Therapeutics Announces Workforce Reduction GlobeNewswire
Aug-28-18 07:00AM  Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer GlobeNewswire
Aug-21-18 10:49AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Gemphire Therapeutics Inc. GlobeNewswire
Aug-13-18 04:01PM  Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire -7.78%
Aug-10-18 07:04AM  Gemphire Therapeutics stock plunges after trial halted due to 'unanticipated problems' MarketWatch -44.95%
06:00AM  Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD GlobeNewswire
Aug-07-18 08:23AM  The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel Benzinga -50.54%
Aug-06-18 04:01PM  Gemphire Provides Update On Development of Gemcabene GlobeNewswire
04:01PM  Gemphire Announces Amended and Restated Gemcabene License Agreement with Pfizer Inc. GlobeNewswire
Jun-29-18 09:01AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +94.47%
08:11AM  Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos Benzinga
08:10AM  Todays Research Reports on Stocks to Watch: Teva Pharmaceuticals and Gemphire Therapeutics ACCESSWIRE
Jun-28-18 04:01PM  Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients GlobeNewswire -5.07%
May-18-18 09:29AM  Gemphire Therapeutics Provides the American Liver Foundation an Educational Grant in Support of Disease State Awareness for Pediatric NAFLD GlobeNewswire
May-16-18 10:51AM  Why Gemphire Therapeutics Incs (NASDAQ:GEMP) Ownership Structure Is Important Simply Wall St. +14.05%
May-08-18 04:01PM  Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-03-18 04:01PM  Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer GlobeNewswire
Apr-12-18 04:01PM  Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire
Mar-16-18 03:16PM  Edited Transcript of GEMP earnings conference call or presentation 15-Mar-18 8:30pm GMT Thomson Reuters StreetEvents
Mar-15-18 04:01PM  Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results GlobeNewswire
08:22AM  Gemphire Therapeutics Inc (NASDAQ:GEMP): Are Analysts Optimistic? Simply Wall St.
Mar-13-18 09:18AM  Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15 GlobeNewswire
Mar-08-18 08:00AM  Gemphire to Present at Two Investor Conferences GlobeNewswire -5.82%
Feb-27-18 04:01PM  Gemphire Expert Panel Call on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH to be Rescheduled GlobeNewswire
Feb-26-18 10:45AM  Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock? Zacks
Feb-21-18 06:00AM  Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH GlobeNewswire
Feb-12-18 06:15PM  Gemphire Therapeutics Inc (GEMP) Interim President & CEO Steven R. Ph.d. ... GuruFocus.com
Feb-08-18 09:00AM  Gemphire Announces Pricing of $22 Million Public Offering of Common Stock GlobeNewswire -27.69%
Feb-07-18 04:32PM  Gemphire Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-31-18 04:01PM  Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD) GlobeNewswire
Jan-17-18 06:30AM  Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia (SHTG) Patients GlobeNewswire +7.28%
Dec-29-17 07:45PM  What Should We Expect From Gemphire Therapeutics Incs (NASDAQ:GEMP) Earnings In The Years Ahead? Simply Wall St.
Dec-26-17 07:00AM  Blog Exposure - Gemphire Therapeutics Launches Clinical Program for Developing Gemcabene as Treatment for NASH/NAFLD ACCESSWIRE
Dec-21-17 06:00AM  Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program GlobeNewswire
Nov-22-17 06:00AM  Gemphire to Present at the Piper Jaffray and LD Micro Investor Conferences GlobeNewswire
Nov-13-17 01:30PM  Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-02-17 07:00AM  Accomplished BioPharma Executive Mina Sooch Joins BioVie Board of Directors and Purchases Company Stock Marketwired
Oct-23-17 08:00AM  Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017 GlobeNewswire
Sep-25-17 09:00AM  Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit GlobeNewswire
Sep-19-17 04:01PM  Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development GlobeNewswire
Sep-18-17 08:00AM  Gemphire to Present at Cantor Fitzgerald Global Healthcare Conference on September 26 in New York GlobeNewswire
Sep-14-17 04:36PM  Gemphire to Host Investor Conference Call to Discuss Future Development Plans for Gemcabene GlobeNewswire
Aug-14-17 06:00AM  Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Aug-07-17 11:57AM  Gemphire Therapeutics Inc. (Nasdaq: GEMP) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
10:00AM  Gemphire to Present at the Canaccord Genuity Growth Conference 2017 GlobeNewswire
06:00AM  Gemphire Announces Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients GlobeNewswire
Aug-01-17 04:30PM  Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jul-25-17 08:00AM  Gemphire Enters Into $15 Million Term Loan Agreement With Silicon Valley Bank GlobeNewswire
Jul-14-17 08:15AM  Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 9.7% Zacks
Jun-28-17 04:01PM  Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients GlobeNewswire
Jun-01-17 08:00AM  Gemphire to Present at the LD Micro Invitational and the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-31-17 09:41AM  Stocks to Watch: Amazon, Alphabet, Michael Kors, Gemphire Therapeutics The Wall Street Journal
May-30-17 04:01PM  Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch GlobeNewswire
May-09-17 06:00AM  Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
May-04-17 02:21PM  Gemphire to Host Key Opinion Leader Lunch on the Evolving NASH Landscape GlobeNewswire
May-01-17 06:00AM  Gemphire to Present at ATVB|PVD 2017 Scientific Sessions GlobeNewswire
Mar-29-17 04:30PM  Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Mar-24-17 01:04PM  GEMPHIRE THERAPEUTICS INC. Financials
10:48AM  Gemphire Therapeutics (GEMP) is in Overbought Territory: What's Next? Zacks
Mar-23-17 08:35AM  Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 12% Zacks
Mar-21-17 09:17AM  Gemphire Therapeutics Announces Presentation at ACC Meeting of Phase 2 Clinical Trial Investigating Effect of Gemcabene on Insulin Sensitization GlobeNewswire
06:06AM  GEMPHIRE THERAPEUTICS INC. Files SEC form 10-K, Annual Report
Mar-16-17 03:52PM  Gemphire to Present at the Oppenheimer Annual Healthcare Conference and the H.C. Wainwright NASH Investor Event GlobeNewswire
Mar-15-17 04:30PM  Gemphire Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today
04:08PM  GEMPHIRE THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:01PM  Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update GlobeNewswire
07:07AM  Q4 2016 Gemphire Therapeutics Inc Earnings Release - After Market Close
Mar-13-17 05:10PM  GEMPHIRE THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
06:30AM  Gemphire Therapeutics to Report Fiscal Year End 2016 Financial Results on Wednesday, March 15 GlobeNewswire
Mar-10-17 09:34AM  Gemphire Therapeutics Announces $12.5 Million Financing GlobeNewswire
09:26AM  GEMPHIRE THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial
Feb-07-17 06:31AM  GEMPHIRE THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-03-17 04:24PM  Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides Investor's Business Daily
04:24PM  Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides
Feb-02-17 06:00AM  Gemphire Therapeutics to Participate in the Canaccord Genuity Rare Disease and Biopharma 1 on 1 Day and the RBC Capital Markets Global Healthcare Conference GlobeNewswire
Jan-30-17 06:00AM  Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial GlobeNewswire
Jan-18-17 05:00PM  Gemphire Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-09-17 08:00AM  Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study GlobeNewswire
Jan-05-17 08:40AM  Gemphire Therapeutics Provides Clinical Update GlobeNewswire
Jan-04-17 03:40PM  LifeSci Capital Initiates Coverage of Gemphire Therapeutics Accesswire
Dec-20-16 12:03AM  How Xenon Pharmaceuticals Inc (XENE) Stacks Up Against Its Peers at Insider Monkey
Dec-19-16 02:00PM  Three Appealing Micro-Cap Stocks
Nov-29-16 04:15PM  Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-28-16 11:07AM  CORRECTING and REPLACING Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia GlobeNewswire
06:00AM  Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia GlobeNewswire
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.